Trial opens door for more testing of hepatitis C vaccine

01/9/2012 | Medical News Today

British researchers used an adenoviral vector strategy to develop a vaccine that can strengthen T cells' response against the hepatitis C virus. The study, published in the journal Science Translational Medicine, found the vaccine to be safe. Researchers are working on a second-stage trial among people infected with the virus, and a U.S. trial is being planned to study whether the vaccine can protect people at risk of infection.

View Full Article in:

Medical News Today

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Payer Marketing
Avalere Health
Washington, DC
Chief Quality Officer
UnityPoint Clinic
Des Moines, ID
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX
The Pew Charitable Trusts
Director, Antibiotics and Innovation Project
Washington, DC
Senior Officer, Drugs and Medical Devices
The Pew Charitable Trusts
Washington, DC